Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial

被引：2

作者：

Santini, Valeria ^{[1
]}

Fenaux, Pierre ^{[2
]}

Zeidan, Amer M. ^{[3
,4
]}

Komrokji, Rami S. ^{[5
]}

Buckstein, Rena ^{[6
]}

Oliva, Esther Natalie ^{[7
]}

Ha, Xianwei ^{[8
]}

Miteva, Dimana ^{[9
]}

Yucel, Aylin ^{[8
]}

Nadal, Jose Alberto ^{[9
]}

Platzbecker, Uwe ^{[10
]}

机构：

[1] Univ Florence, Florence, Italy

[2] Hop St Louis, Assistance Publ Hop Paris AP HP, Paris, France

[3] Yale Univ, Yale Sch Med, New Haven, CT USA

[4] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[6] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada

[7] Grande Osped Metropolitano Bianchi Melacrino More, Reggio Di Calabria, Italy

[8] Bristol Myers Squibb, Princeton, NJ USA

[9] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland

[10] Univ Leipzig, Med Ctr, Dept Hematol Cell Therapy & Hemostaseol, Leipzig, Germany

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157489

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4079 / 4081

页数：3

共 50 条

[31] Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint
Rosenberg, Aaron S.
Facon, Thierry
Parikh, Kejal
Chung, Weiyuan
Srinivasan, Shankar
Kotey, Stanley
Tuscano, Joseph
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (05): : 345 - +
[32] Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS)
Stewart, David J.
Bosse, Dominick
Hilton, John Frederick
Goss, Glenwood D.
Fung-Kee-Fung, Michael
Jonker, Derek J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[33] Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma
Hemi Malkki
Nature Reviews Neurology, 2014, 10 (4) : 179 - 179
[34] Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
Beauchemin, Catherine
Cooper, Dan
Lapierre, Marie-Eve
Yelle, Louise
Lachaine, Jean
ONCOTARGETS AND THERAPY, 2014, 7 : 1101 - 1110
[35] Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study
Zhang, Lijun
Ko, Chia-Wen
Tang, Shenghui
Sridhara, Rajeshwari
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2013, 47 (01) : 95 - 100
[36] RELATIONSHIP BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
Beauchemin, C.
Johnston, J.
Lapierre, M. E.
Aissa, F.
Lachaine, J.
VALUE IN HEALTH, 2012, 15 (07) : A414 - A415
[37] Prognostic Factors for Progression-free Survival and Overall Survival Αfter Recurrence of Glioblastoma
Zemskova, Oksana
Yu, Nathan y.
Leppert, Jan
Rades, Dirk
ANTICANCER RESEARCH, 2024, 44 (07) : 3059 - 3066
[38] Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study
Lijun Zhang
Chia-Wen Ko
Shenghui Tang
Rajeshwari Sridhara
Therapeutic Innovation & Regulatory Science, 2013, 47 : 95 - 100
[39] RELATIONSHIP BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
Beauchemin, C.
Johnston, J. B.
Lapierre, M.
Aissa, F.
Lachaine, J.
ANNALS OF ONCOLOGY, 2012, 23 : 350 - 350
[40] Influence of clinical trial participation with regard to overall survival (OS) and progression-free survival (PFS) for patients with advanced breast cancer
Kiechle, M.
Simstich, N. S.
Schwarz-Boeger, U. R.
Paepke, S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →